Mizuho analyst Graig Suvannavejh reiterated a Neutral rating and $1.00 price target on BioXcel Therapeutics (NASDAQ: BTAI).The analyst commented: "Yesterday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE